Li C - Search Results

1

Targeting CD22 for B-cell hematologic malignancies.

Xu J, Luo W, Li C, Mei H. Xu J, et al. Among authors: li c. Exp Hematol Oncol. 2023 Oct 11;12(1):90. doi: 10.1186/s40164-023-00454-7. Exp Hematol Oncol. 2023. PMID: 37821931 Free PMC article. Review.

2

Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis.

Tang L, Peng YZ, Li CG, Jiang HW, Mei H, Hu Y. Tang L, et al. J Cancer. 2019 Jan 1;10(3):654-664. doi: 10.7150/jca.28537. eCollection 2019. J Cancer. 2019. PMID: 30719163 Free PMC article. Review.

3

Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.

Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, Wu Y, Zhou F, Ai L, Shi W, Lu X, Wang H, Tang L, Wei Q, Deng J, Jin R, Xiong W, Dong J, Mei H, Hu Y. Jiang H, et al. Among authors: li c. Am J Hematol. 2019 Oct;94(10):1113-1122. doi: 10.1002/ajh.25582. Epub 2019 Aug 2. Am J Hematol. 2019. PMID: 31321805 Free article. Clinical Trial.

4

Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.

Tang L, Zhang H, Peng YZ, Li CG, Jiang HW, Xu M, Mei H, Hu Y. Tang L, et al. BMC Cancer. 2019 Aug 28;19(1):849. doi: 10.1186/s12885-019-6039-9. BMC Cancer. 2019. PMID: 31462241 Free PMC article.

5

Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia.

Tang L, Wu J, Li CG, Jiang HW, Xu M, Du M, Yin Z, Mei H, Hu Y. Tang L, et al. Clin Cancer Res. 2020 Apr 1;26(7):1763-1772. doi: 10.1158/1078-0432.CCR-19-3003. Epub 2020 Jan 7. Clin Cancer Res. 2020. PMID: 31911547

6

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.

Li C, Mei H, Hu Y. Li C, et al. Brief Funct Genomics. 2020 May 20;19(3):175-182. doi: 10.1093/bfgp/elz042. Brief Funct Genomics. 2020. PMID: 31950135 Free PMC article. Review.

7

[Application Advance of Flow Cytometry in the CAR-T Cell Therapy--Review].

Li CG, Mei H, Hu Y. Li CG, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Feb;28(1):329-332. doi: 10.19746/j.cnki.issn.1009-2137.2020.01.055. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020. PMID: 32027298 Review. Chinese.

8

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.

Li C, Sun Y, Wang J, Tang L, Jiang H, Guo T, Liu L, Wu Y, Ai L, Xia L, Wu J, Lin Z, Qian Q, Hu Y, Mei H. Li C, et al. Front Immunol. 2021 May 25;12:599493. doi: 10.3389/fimmu.2021.599493. eCollection 2021. Front Immunol. 2021. PMID: 34113336 Free PMC article. Clinical Trial.

9

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.

Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, Yin P, Wang Z, Ai L, Ke S, Xia Y, Deng J, Chen L, Cai L, Sun C, Xia L, Hua G, Hu Y. Mei H, et al. Among authors: li c. J Hematol Oncol. 2021 Oct 9;14(1):161. doi: 10.1186/s13045-021-01170-7. J Hematol Oncol. 2021. PMID: 34627333 Free PMC article. Clinical Trial.

10

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.

Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, Mei H, Hu Y. Luo W, et al. Among authors: li c. BMC Cancer. 2022 Jan 24;22(1):98. doi: 10.1186/s12885-021-09102-x. BMC Cancer. 2022. PMID: 35073859 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89,064 results

Search Page

Filters